Technical Analysis for ENZ - Enzo Biochem, Inc.

Grade Last Price % Change Price Change
grade F 2.57 -1.53% -0.04
ENZ closed down 1.53 percent on Friday, March 22, 2019, on 1.13 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ENZ trend table...

Date Alert Name Type % Chg
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Shooting Star Candlestick Bearish -1.53%
Mar 21 1,2,3 Retracement Bearish Bearish Swing Setup -1.53%
Mar 21 180 Bearish Setup Bearish Swing Setup -1.53%
Mar 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.53%
Mar 21 Wide Bands Range Expansion -1.53%
Mar 21 Oversold Stochastic Weakness -1.53%
Mar 20 1,2,3 Retracement Bearish Bearish Swing Setup -2.28%
Mar 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.28%

Older signals for ENZ ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory, a network of approximately 30 patient service centers, a laboratory, and a full-service phlebotomy and in-house logistics department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It provides proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which offer tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts primarily in the field of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment researches and develops therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company sells its products through its direct sales force; and a network of distributors worldwide. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Biotechnology Cancer Life Sciences Diabetes Antibodies Obesity Drug Development Gene Expression Neurological Disorders Cardiovascular Disease Genetic Engineering Two River Metabolic Diseases Medical Diagnosis Medical Laboratory Endocrine Disorders
Is ENZ a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.89
52 Week Low 2.32
Average Volume 171,175
200-Day Moving Average 3.9105
50-Day Moving Average 3.382
20-Day Moving Average 3.0005
10-Day Moving Average 2.697
Average True Range 0.1623
ADX 39.16
+DI 9.1217
-DI 30.4849
Chandelier Exit (Long, 3 ATRs ) 3.1631
Chandelier Exit (Short, 3 ATRs ) 2.9969
Upper Bollinger Band 3.7183
Lower Bollinger Band 2.2827
Percent B (%b) 0.2
BandWidth 47.845359
MACD Line -0.2463
MACD Signal Line -0.21
MACD Histogram -0.0363
Fundamentals Value
Market Cap 119.62 Million
Num Shares 46.5 Million
EPS -0.05
Price-to-Earnings (P/E) Ratio -51.40
Price-to-Sales 4.40
Price-to-Book 5.34
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.74
Resistance 3 (R3) 2.74 2.70 2.71
Resistance 2 (R2) 2.70 2.65 2.69 2.70
Resistance 1 (R1) 2.63 2.63 2.61 2.63 2.69
Pivot Point 2.59 2.59 2.58 2.58 2.59
Support 1 (S1) 2.52 2.54 2.50 2.52 2.45
Support 2 (S2) 2.48 2.52 2.47 2.44
Support 3 (S3) 2.41 2.48 2.43
Support 4 (S4) 2.41